AMGN Quote, Financials, Valuation and Earnings

Gilead Sciences has a net margin of 21.23% compared to Amgen's net margin of 19.72%. Amgen's return on equity of 97.08% beat Gilead Sciences's return on equity of 32.29%.

Amgen has a consensus price target of $315.35, signalling upside risk potential of 14.32%. On the other hand Gilead Sciences has an analysts' consensus of $115.04 which suggests that it could grow by 16.32%. Given that Gilead Sciences has higher upside potential than Amgen, analysts believe Gilead Sciences is more attractive than Amgen.

Amgen has a beta of 0.502, which suggesting that the stock is 49.829% less volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.263, suggesting its less volatile than the S&P 500 by 73.697%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.31%. Gilead Sciences offers a yield of 3.14% to investors and pays a quarterly dividend of $0.79 per share. Amgen pays 118.14% of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend. Neither of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Amgen quarterly revenues are $8.1B, which are larger than Gilead Sciences quarterly revenues of $6.7B. Amgen's net income of $1.7B is higher than Gilead Sciences's net income of $1.3B. Notably, Amgen's price-to-earnings ratio is 25.17x while Gilead Sciences's PE ratio is 20.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.37x versus 4.34x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of 21.23% compared to Amgen's net margin of 50.24%. Amgen's return on equity of 97.08% beat Johnson & Johnson's return on equity of 30.18%.

Amgen has a consensus price target of $315.35, signalling upside risk potential of 14.32%. On the other hand Johnson & Johnson has an analysts' consensus of $170.19 which suggests that it could grow by 8.2%. Given that Amgen has higher upside potential than Johnson & Johnson, analysts believe Amgen is more attractive than Johnson & Johnson.

Amgen has a beta of 0.502, which suggesting that the stock is 49.829% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.31%. Johnson & Johnson offers a yield of 3.15% to investors and pays a quarterly dividend of $1.24 per share. Amgen pays 118.14% of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Amgen's is not.

Amgen quarterly revenues are $8.1B, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Amgen's net income of $1.7B is lower than Johnson & Johnson's net income of $11B. Notably, Amgen's price-to-earnings ratio is 25.17x while Johnson & Johnson's PE ratio is 17.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.37x versus 4.27x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 21.23% compared to Amgen's net margin of -907.48%. Amgen's return on equity of 97.08% beat Moderna's return on equity of -29.23%.

Amgen has a consensus price target of $315.35, signalling upside risk potential of 14.32%. On the other hand Moderna has an analysts' consensus of $46.96 which suggests that it could grow by 95.19%. Given that Moderna has higher upside potential than Amgen, analysts believe Moderna is more attractive than Amgen.

Amgen has a beta of 0.502, which suggesting that the stock is 49.829% less volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.31%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays 118.14% of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $8.1B, which are larger than Moderna quarterly revenues of $107M. Amgen's net income of $1.7B is higher than Moderna's net income of -$971M. Notably, Amgen's price-to-earnings ratio is 25.17x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.37x versus 2.98x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of 21.23% compared to Amgen's net margin of 26.7%. Amgen's return on equity of 97.08% beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Amgen has a consensus price target of $315.35, signalling upside risk potential of 14.32%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $800.13 which suggests that it could grow by 42.64%. Given that Regeneron Pharmaceuticals has higher upside potential than Amgen, analysts believe Regeneron Pharmaceuticals is more attractive than Amgen.

Amgen has a beta of 0.502, which suggesting that the stock is 49.829% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.427, suggesting its less volatile than the S&P 500 by 57.331%.

Amgen has a quarterly dividend of $2.38 per share corresponding to a yield of 3.31%. Regeneron Pharmaceuticals offers a yield of 0.16% to investors and pays a quarterly dividend of $0.88 per share. Amgen pays 118.14% of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Amgen quarterly revenues are $8.1B, which are larger than Regeneron Pharmaceuticals quarterly revenues of $3B. Amgen's net income of $1.7B is higher than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Amgen's price-to-earnings ratio is 25.17x while Regeneron Pharmaceuticals's PE ratio is 14.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.37x versus 4.54x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.